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A Restrospective Analysis of the Association of Obesity with Anthracycline and Trastuzumab
Induced Cardiotoxicity in the Treatment of Cancer
• Anthracycline (AC) and Trastuzumab (Tra) have 
been shown to cause significant cardiotoxicity
(CT)
• AC induced CT has been cited as high as 26% 
when higher cumulative doses were used (6)
• CT is about 3% to 7% with Tra (7)
• CT is defined as patient with documented 
diagnoses of heart failure on the chart, 
decrease in LVEF either >15% from baseline or 
LVEF<50%, or documented acute coronary 
syndrome after AC or Tra based chemotherapy 
was initiated 
• Doses of AC are calculated based on body 
surface area (BSA) and for Tra based on body 
weight 
– Obese patients receive a higher cumulative dose of 
chemotherapy
• Obesity is inconsistently listed as a risk factor 
for CT 
• We wanted to confirm if there was a link 
between obesity and CT from AC and/or Tra
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• Retrospective analysis of all patients who 
have received AC and/or Tra as part of their 
chemotherapy treatment between 2008 and 
2012
• All of the information was collected from 
MOSAIQ, EPIC, and Centricity 
• Data collected includes: 
– cancer type, chemotherapy type, dose and duration
– Age, gender, height, weight, BMI, BSA
– Creatinine clearance, hemoglobin, albumin, lipids, 
blood pressure, glucose level
– Hospital or outpatient evaluations for congestive 
heart failure or shortness of breath, such as, echo, 
MUGA, BNP, NT-proBNP, troponin, stress testing,  
and cardiac catheterization
– Past heart problems
• Age range of patients who acquired CT is 27- 79  
• In the cohort without CT only 40% were obese but 
within the group that developed CT 50% were obese 
• Obese patients that developed CT got an average 
cumulative dose of 498 mg of AC or an average 
cumulative dose of 15,240 mg of Tra compared to the 
obese non-CT patients who received an average 
cumulative dose of 479 mg of AC or 10,434 mg of Tra
• Within the group of patients who had CT there was a 
high percent of patients with hypertension and/or  
diabetes 
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• Out of the 215 people that received AC 10.2% got CT 
• Out of 97 people that received Tra 4.1% got CT 
• Out of 23 people who received both AC and Tra 8.7% got CT
